Cargando…
Incremental burden of comorbid major depressive disorder in patients with type 2 diabetes or cardiovascular disease: a retrospective claims analysis
BACKGROUND: The estimated prevalence of comorbid major depressive disorder (. MDD) is 11% in patients with type 2 diabetes (T2D) and 15–20% in those with cardiovascular disease (CVD). Comorbid MDD continues to be a significant source of economic burden to the healthcare system. METHODS: We assessed...
Autores principales: | Kangethe, Anne, Lawrence, Debra F., Touya, Maëlys, Chrones, Lambros, Polson, Michael, Evangelatos, Themmi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349073/ https://www.ncbi.nlm.nih.gov/pubmed/34362353 http://dx.doi.org/10.1186/s12913-021-06802-9 |
Ejemplares similares
-
Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data
por: Touya, Maëlys, et al.
Publicado: (2022) -
Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice: US cohort results from the global RELIEVE study
por: Mattingly, Gregory, et al.
Publicado: (2023) -
Patient Expectations and Experiences of Antidepressant Therapy for Major Depressive Disorder: A Qualitative Study
por: Baune, Bernhard T, et al.
Publicado: (2021) -
Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
por: Jacobsen, Paula L., et al.
Publicado: (2015) -
O8.5. SCHIZOPHRENIA AND BIPOLAR DISORDER DIAGNOSIS PATTERNS: REAL-WORLD EVIDENCE FROM US CLAIMS DATABASES
por: Greene, Mallik, et al.
Publicado: (2018)